Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter Study

被引:4
|
作者
Kroeger, Kai [1 ]
Siats, Jan [1 ]
Kerkhoff, Andrea [2 ]
Lenz, Georg [2 ]
Stelljes, Matthias [2 ]
Eich, Hans Theodor [1 ]
Reinartz, Gabriele [1 ]
机构
[1] Univ Hosp Muenster, Dept Radiat Oncol, Albert Schweitzer Campus 1,Bldg 1A, D-48419 Munster, Germany
[2] Univ Hosp Muenster, Dept Hematol & Oncol, Bone Marrow Transplantat Unit, Albert Schweitzer Campus 1,Bldg 1A, D-48419 Munster, Germany
关键词
mantle cell lymphoma; total body irradiation; stem cell transplantation; BONE-MARROW-TRANSPLANTATION; OPEN-LABEL; CONDITIONING REGIMENS; RANDOMIZED-TRIAL; 1ST REMISSION; IBRUTINIB; BUSULFAN; BLOOD;
D O I
10.3390/cancers15030983
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mantle cell lymphoma (MCL) is a very rare subtype of non-Hodgkin's lymphoma, predominantly affecting men, where most patients at initial presentation show an advanced spread of the disease with poor prognosis. We analyzed the long-term outcome of 22 patients treated with total body irradiation (TBI)-based conditioning prior to stem cell transplantation (SCT) at the University Hospital of Muenster, Germany. The present results of multimodal treatment support the published reports that TBI-based high-dose therapy followed by SCT is highly effective in this unfavorable disease. Both recently approved agents and traditional SCT open up possibilities of a personalized treatment approach for MCL with the aim of a cure. Introduction: In patients with mantle cell lymphoma (MCL), long-term remissions can be achieved by stem cell transplantation (SCT). Different conditioning treatment protocols exist with or without total body irradiation (TBI). There are few data published on the role of TBI before autologous stem cell transplantation (autoSCT) or allogenic stem cell transplantation (alloSCT). We report on the long-term survival data of patients treated by TBI prior to autologous or allogenic SCT at our center. Patients: In a retrospective analysis, the data of patients treated at the University Hospital of Muenster from May 2004 to February 2015 were collected and evaluated. For the analysis, all data of patients who were histopathologically diagnosed with MCL and underwent TBI prior to stem cell transplantation (SCT) were evaluated. Results: A total of 22 patients (19 men and 3 women) were treated with a TBI-based conditioning prior to SCT. The median age at initial diagnosis was 57.5 years (38-65 years). Seventeen patients had Ann Arbor stage IV, two patients had Ann Arbor stage III, and three patients Ann Arbor stage II disease. AutoSCT was performed in 19 patients and alloSCT was performed in 3 patients. In 18 patients, autoSCT was applied as part of first-line therapy, and in one patient after relapse. Two patients received alloSCT after relapse of MCL, and one patient received alloSCT during first-line therapy after an inadequate treatment response. TBI was performed in 12 patients with 10 Gy and in 6 patients with 12 Gy, these patients subsequently received autoSCT. In the group of four patients who received TBI with four Gy, four patients subsequently received alloSCT and one patient received autoSCT. Median overall survival after autoSCT and previous TBI was 11.4 years (142 months). In total, 11 out of 19 patients treated with autoSCT lived longer than 6.8 years (82-202 months). After alloSCT and previous TBI, the median overall survival was 3.25 years (14-59 months). Conclusions: A large proportion of patients with advanced MCL survived remarkably longer than 11.4 years after high-dose chemotherapy, TBI, and SCT. The present results of multimodal treatment support the published reports that TBI-based high-dose therapy followed by autoSCT is highly effective in this prognostically unfavorable disease situation.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Long-term Survival in Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-dose Chemotherapy and Stem Cell Transplantation
    Kroger, K.
    Siats, J.
    Stelljes, M.
    Lenz, G.
    Eich, H. T.
    Reinartz, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S172 - S172
  • [2] Long-Term Surviving Patients with Mantle Cell Lymphoma after Total Body Radiation, High-Dose Chemotherapy and Stem Cell Transplantation
    Kroeger, K.
    Luebke, J.
    Lauterborn, H.
    Stelljes, M.
    Eich, H. T.
    Reinartz, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S167 - S167
  • [3] Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation
    Metzner, Bernd
    Mueller, Thomas H.
    Casper, Jochen
    Kimmich, Christoph
    Koehne, Claus-Henning
    Petershofen, Eduard
    Renzelmann, Andrea
    Thole, Ruth
    Voss, Andreas
    Dreyling, Martin
    Hoster, Eva
    Klapper, Wolfram
    Pott, Christiane
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) : 220 - 228
  • [4] Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation
    Schetelig, J
    Fetscher, S
    Reichle, A
    Berdel, WE
    Beguin, Y
    Brunet, S
    Caballero, D
    Majolino, I
    Hagberg, H
    Johnsen, HE
    Kimby, E
    Montserrat, E
    Stewart, D
    Copplestone, A
    Rösler, W
    Pavel, J
    Kingreen, D
    Siegert, W
    HAEMATOLOGICA, 2003, 88 (11) : 1272 - 1278
  • [5] Long-term survival of a broad age population of patients with mantle cell lymphoma after frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation
    Cortelazzo, S.
    Billio, A.
    Magni, M.
    Rossi, A.
    Pintimalli, M.
    Marchesi, M.
    Zanni, M.
    Mian, M.
    Tarella, C.
    Boccadoro, M.
    Andreini, A.
    Benedetti, F.
    Pizzolo, G.
    Gianni, M.
    Rambaldi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 269 - 269
  • [6] Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
    Jo S Stenehjem
    Knut B Smeland
    Klaus Murbraech
    Harald Holte
    Stein Kvaløy
    Lene Thorsen
    Ingerid Arbo
    Lee W Jones
    Svend Aakhus
    May Brit Lund
    Cecilie E Kiserud
    British Journal of Cancer, 2016, 115 : 178 - 187
  • [7] Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
    Stenehjem, Jo S.
    Smeland, Knut B.
    Murbraech, Klaus
    Holte, Harald
    Kvaloy, Stein
    Thorsen, Lene
    Arbo, Ingerid
    Jones, Lee W.
    Aakhus, Svend
    Lund, May Brit
    Kiserud, Cecilie E.
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 178 - 187
  • [8] Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation
    Metzner, Bernd
    Mueller, Thomas H.
    Gebauer, Wolfgang
    Casper, Jochen
    Kraemer, Doris
    Rosien, Bernd
    Schumann-Binarsch, Silke
    Thole, Ruth
    Koehne, Claus H.
    Dreyling, Martin
    Hoster, Eva
    Pott, Christiane
    ANNALS OF HEMATOLOGY, 2014, 93 (05) : 803 - 810
  • [9] Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation
    Bernd Metzner
    Thomas H. Müller
    Wolfgang Gebauer
    Jochen Casper
    Doris Kraemer
    Bernd Rosien
    Silke Schumann-Binarsch
    Ruth Thole
    Claus H. Köhne
    Martin Dreyling
    Eva Hoster
    Christiane Pott
    Annals of Hematology, 2014, 93 : 803 - 810
  • [10] Factors related to unemployment in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
    Kiserud, Cecilie E.
    Fagerli, Unn Merete
    Smeland, Knut Halvor B.
    Kvaloy, Stein
    Holte, Harald
    Dahl, Alv A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)